Mechanisms of immune activation and regulation: lessons from melanoma.
Journal
Nature reviews. Cancer
ISSN: 1474-1768
Titre abrégé: Nat Rev Cancer
Pays: England
ID NLM: 101124168
Informations de publication
Date de publication:
04 2022
04 2022
Historique:
accepted:
04
01
2022
pubmed:
3
2
2022
medline:
2
4
2022
entrez:
2
2
2022
Statut:
ppublish
Résumé
Melanoma, a skin cancer that develops from pigment cells, has been studied intensively, particularly in terms of the immune response to tumours, and has been used as a model for the development of immunotherapy. This is due, in part, to the high mutational burden observed in melanomas, which increases both their immunogenicity and the infiltration of immune cells into the tumours, compared with other types of cancers. The immune response to melanomas involves a complex set of components and interactions. As the tumour evolves, it accumulates an increasing number of genetic and epigenetic alterations, some of which contribute to the immunogenicity of the tumour cells and the infiltration of immune cells. However, tumour evolution also enables the development of resistance mechanisms, which, in turn, lead to tumour immune escape. Understanding the interactions between melanoma tumour cells and the immune system, and the evolving changes within the melanoma tumour cells, the immune system and the microenvironment, is essential for the development of new cancer therapies. However, current research suggests that other extrinsic factors, such as the microbiome, may play a role in the immune response to melanomas. Here, we review the mechanisms underlying the immune response in the tumour and discuss recent advances as well as strategies for treatment development.
Identifiants
pubmed: 35105962
doi: 10.1038/s41568-022-00442-9
pii: 10.1038/s41568-022-00442-9
doi:
Types de publication
Journal Article
Review
Research Support, N.I.H., Intramural
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
195-207Informations de copyright
© 2022. Springer Nature Limited.
Références
Cancer Genome Atlas Network. Genomic classification of cutaneous melanoma. Cell 161, 1681–1696 (2015).
doi: 10.1016/j.cell.2015.05.044
Long, G. V. et al. Dabrafenib and trametinib versus dabrafenib and placebo for Val600 BRAF-mutant melanoma: a multicentre, double-blind, phase 3 randomised controlled trial. Lancet 386, 444–451 (2015).
pubmed: 26037941
doi: 10.1016/S0140-6736(15)60898-4
Salgaller, M. L., Weber, J. S., Koenig, S., Yannelli, J. R. & Rosenberg, S. A. Generation of specific anti-melanoma reactivity by stimulation of human tumor-infiltrating lymphocytes with MAGE-1 synthetic peptide. Cancer Immunol. Immunother. 39, 105–116 (1994).
pubmed: 7519125
doi: 10.1007/BF01525316
Blass, E. & Ott, P. A. Advances in the development of personalized neoantigen-based therapeutic cancer vaccines. Nat. Rev. Clin. Oncol. 18, 215–229 (2021).
pubmed: 33473220
pmcid: 7816749
doi: 10.1038/s41571-020-00460-2
Callahan, M. K. et al. Nivolumab plus ipilimumab in patients with advanced melanoma: updated survival, response, and safety data in a phase I dose-escalation study. J. Clin. Oncol. 36, 391–398 (2018).
pubmed: 29040030
doi: 10.1200/JCO.2017.72.2850
Fridman, W. H., Pages, F., Sautes-Fridman, C. & Galon, J. The immune contexture in human tumours: impact on clinical outcome. Nat. Rev. Cancer 12, 298–306 (2012).
pubmed: 22419253
doi: 10.1038/nrc3245
Gajewski, T. F. Failure at the effector phase: immune barriers at the level of the melanoma tumor microenvironment. Clin. Cancer Res. 13, 5256–5261 (2007).
pubmed: 17875753
doi: 10.1158/1078-0432.CCR-07-0892
Anichini, A., Vegetti, C. & Mortarini, R. The paradox of T-cell-mediated antitumor immunity in spite of poor clinical outcome in human melanoma. Cancer Immunol. Immunother. 53, 855–864 (2004).
pubmed: 15175905
doi: 10.1007/s00262-004-0526-8
Larkin, J. et al. Combined nivolumab and ipilimumab or monotherapy in untreated melanoma. N. Engl. J. Med. 373, 23–34 (2015).
pubmed: 26027431
pmcid: 5698905
doi: 10.1056/NEJMoa1504030
Robert, C. et al. Pembrolizumab versus ipilimumab in advanced melanoma. N. Engl. J. Med. 372, 2521–2532 (2015).
pubmed: 25891173
doi: 10.1056/NEJMoa1503093
Wolchok, J. D. et al. Overall survival with combined nivolumab and ipilimumab in advanced melanoma. N. Engl. J. Med. 377, 1345–1356 (2017).
pubmed: 28889792
pmcid: 5706778
doi: 10.1056/NEJMoa1709684
Larkin, J. et al. Five-year survival with combined nivolumab and ipilimumab in advanced melanoma. N. Engl. J. Med. 381, 1535–1546 (2019).
pubmed: 31562797
doi: 10.1056/NEJMoa1910836
Tran, E., Robbins, P. F. & Rosenberg, S. A. ‘Final common pathway’ of human cancer immunotherapy: targeting random somatic mutations. Nat. Immunol. 18, 255–262 (2017).
pubmed: 28198830
pmcid: 6295671
doi: 10.1038/ni.3682
Haen, S. P., Loffler, M. W., Rammensee, H. G. & Brossart, P. Towards new horizons: characterization, classification and implications of the tumour antigenic repertoire. Nat. Rev. Clin. Oncol. 17, 595–610 (2020).
pubmed: 32572208
pmcid: 7306938
doi: 10.1038/s41571-020-0387-x
Lu, Y. C. et al. Mutated PPP1R3B is recognized by T cells used to treat a melanoma patient who experienced a durable complete tumor regression. J. Immunol. 190, 6034–6042 (2013).
pubmed: 23690473
doi: 10.4049/jimmunol.1202830
Kalaora, S. et al. Combined analysis of antigen presentation and T-cell recognition reveals restricted immune responses in melanoma. Cancer Discov. 8, 1366–1375 (2018).
pubmed: 30209080
pmcid: 6453138
doi: 10.1158/2159-8290.CD-17-1418
Lawrence, M. S. et al. Mutational heterogeneity in cancer and the search for new cancer-associated genes. Nature 499, 214–218 (2013).
pubmed: 23770567
pmcid: 3919509
doi: 10.1038/nature12213
Schumacher, T. N. & Schreiber, R. D. Neoantigens in cancer immunotherapy. Science 348, 69–74 (2015).
pubmed: 25838375
doi: 10.1126/science.aaa4971
Yamamoto, T. N., Kishton, R. J. & Restifo, N. P. Developing neoantigen-targeted T cell-based treatments for solid tumors. Nat. Med. 25, 1488–1499 (2019).
pubmed: 31591590
doi: 10.1038/s41591-019-0596-y
Wolf, Y. et al. UVB-induced tumor heterogeneity diminishes immune response in melanoma. Cell 179, 219–235.e21 (2019).
pubmed: 31522890
pmcid: 6863386
doi: 10.1016/j.cell.2019.08.032
Reuben, A. et al. Genomic and immune heterogeneity are associated with differential responses to therapy in melanoma. NPJ Genom. Med. 2, 10 (2017).
pubmed: 28819565
pmcid: 5557036
doi: 10.1038/s41525-017-0013-8
Lin, Z. et al. Intratumor heterogeneity correlates with reduced immune activity and worse survival in melanoma patients. Front. Oncol. 10, 596493 (2020).
pubmed: 33344244
pmcid: 7747763
doi: 10.3389/fonc.2020.596493
Williams, J. B. et al. Tumor heterogeneity and clonal cooperation influence the immune selection of IFN-γ-signaling mutant cancer cells. Nat. Commun. 11, 602 (2020).
pubmed: 32001684
pmcid: 6992737
doi: 10.1038/s41467-020-14290-4
Schiavetti, F., Thonnard, J., Colau, D., Boon, T. & Coulie, P. G. A human endogenous retroviral sequence encoding an antigen recognized on melanoma by cytolytic T lymphocytes. Cancer Res. 62, 5510–5516 (2002).
pubmed: 12359761
Kalaora, S. et al. Identification of bacteria-derived HLA-bound peptides in melanoma. Nature 592, 138–143 (2021).
pubmed: 33731925
doi: 10.1038/s41586-021-03368-8
Bach, E. A., Aguet, M. & Schreiber, R. D. The IFNγ receptor: a paradigm for cytokine receptor signaling. Annu. Rev. Immunol. 15, 563–591 (1997).
pubmed: 9143700
doi: 10.1146/annurev.immunol.15.1.563
Paucker, K., Henle, W. & Cantell, K. Quantitative studies on viral interference in suspended L cells. 3. Effect of interfering viruses and interferon on growth rate of cells. Virology 17, 324–334 (1962).
pubmed: 14484446
doi: 10.1016/0042-6822(62)90123-X
Sucker, A. et al. Acquired IFNγ resistance impairs anti-tumor immunity and gives rise to T-cell-resistant melanoma lesions. Nat. Commun. 8, 15440 (2017).
pubmed: 28561041
pmcid: 5460020
doi: 10.1038/ncomms15440
Cole, K. E. et al. Interferon-inducible T cell α chemoattractant (I-TAC): a novel non-ELR CXC chemokine with potent activity on activated T cells through selective high affinity binding to CXCR3. J. Exp. Med. 187, 2009–2021 (1998).
pubmed: 9625760
pmcid: 2212354
doi: 10.1084/jem.187.12.2009
Farber, J. M. A macrophage messenger-RNA selectively induced by γ-interferon encodes a member of the platelet factor-IV family of cytokines. Proc. Natl Acad. Sci. USA 87, 5238–5242 (1990).
pubmed: 2115167
pmcid: 54298
doi: 10.1073/pnas.87.14.5238
Luster, A. D., Unkeless, J. C. & Ravetch, J. V. γ-Interferon transcriptionally regulates an early-response gene containing homology to platelet proteins. Nature 315, 672–676 (1985).
pubmed: 3925348
doi: 10.1038/315672a0
Basham, T. Y. & Merigan, T. C. Recombinant interferon-γ increases HLA-DR synthesis and expression. J. Immunol. 130, 1492–1494 (1983).
pubmed: 6403609
King, D. P. & Jones, P. P. Induction of Ia and H-2 antigens on a macrophage cell line by immune interferon. J. Immunol. 131, 315–318 (1983).
pubmed: 6408177
Kalaora, S. et al. Immunoproteasome expression is associated with better prognosis and response to checkpoint therapies in melanoma. Nat. Commun. 11, 896 (2020).
pubmed: 32060274
pmcid: 7021791
doi: 10.1038/s41467-020-14639-9
Benci, J. L. et al. Tumor interferon signaling regulates a multigenic resistance program to immune checkpoint blockade. Cell 167, 1540–1554.e12 (2016).
pubmed: 27912061
pmcid: 5385895
doi: 10.1016/j.cell.2016.11.022
Zaretsky, J. M. et al. Mutations associated with acquired resistance to PD-1 blockade in melanoma. N. Engl. J. Med. 375, 819–829 (2016).
pubmed: 27433843
pmcid: 5007206
doi: 10.1056/NEJMoa1604958
Manguso, R. T. et al. In vivo CRISPR screening identifies Ptpn2 as a cancer immunotherapy target. Nature 547, 413–418 (2017).
pubmed: 28723893
pmcid: 5924693
doi: 10.1038/nature23270
Patel, S. J. et al. Identification of essential genes for cancer immunotherapy. Nature 548, 537–542 (2017).
pubmed: 28783722
pmcid: 5870757
doi: 10.1038/nature23477
Pan, D. et al. A major chromatin regulator determines resistance of tumor cells to T cell-mediated killing. Science 359, 770–775 (2018). Together with Manguso et al. (2017) and Patel et al. (2017), this paper describes CRISPR screens that identify tumour-intrinsic mechanisms of resistance to immunotherapy using in vitro co-culture of melanoma cells and tumour-specific T cells.
pubmed: 29301958
pmcid: 5953516
doi: 10.1126/science.aao1710
D’Urso, C. M. et al. Lack of HLA class I antigen expression by cultured melanoma cells FO-1 due to a defect in B2m gene expression. J. Clin. Invest. 87, 284–292 (1991).
pubmed: 1898655
pmcid: 295046
doi: 10.1172/JCI114984
Sucker, A. et al. Genetic evolution of T-cell resistance in the course of melanoma progression. Clin. Cancer Res. 20, 6593–6604 (2014).
pubmed: 25294904
pmcid: 8728890
doi: 10.1158/1078-0432.CCR-14-0567
Restifo, N. P. et al. Loss of functional β2-microglobulin in metastatic melanomas from five patients receiving immunotherapy. J. Natl Cancer Inst. 88, 100–108 (1996).
pubmed: 8537970
doi: 10.1093/jnci/88.2.100
Sahin, U. et al. Personalized RNA mutanome vaccines mobilize poly-specific therapeutic immunity against cancer. Nature 547, 222–226 (2017).
pubmed: 28678784
doi: 10.1038/nature23003
Sade-Feldman, M. et al. Resistance to checkpoint blockade therapy through inactivation of antigen presentation. Nat. Commun. 8, 1136 (2017).
pubmed: 29070816
pmcid: 5656607
doi: 10.1038/s41467-017-01062-w
Huang, L. et al. The RNA-binding protein MEX3B mediates resistance to cancer immunotherapy by downregulating HLA-A expression. Clin. Cancer Res. 24, 3366–3376 (2018).
pubmed: 29496759
doi: 10.1158/1078-0432.CCR-17-2483
Rodig, S. J. et al. MHC proteins confer differential sensitivity to CTLA-4 and PD-1 blockade in untreated metastatic melanoma. Sci. Transl. Med. 10, eaar3342 (2018).
pubmed: 30021886
doi: 10.1126/scitranslmed.aar3342
Johnson, D. B. et al. Melanoma-specific MHC-II expression represents a tumour-autonomous phenotype and predicts response to anti-PD-1/PD-L1 therapy. Nat. Commun. 7, 10582 (2016).
pubmed: 26822383
pmcid: 4740184
doi: 10.1038/ncomms10582
Johnson, D. B. et al. Tumor-specific MHC-II expression drives a unique pattern of resistance to immunotherapy via LAG-3/FCRL6 engagement. JCI Insight 3, e120360 (2018).
pmcid: 6338319
doi: 10.1172/jci.insight.120360
Donia, M. et al. Aberrant expression of MHC class II in melanoma attracts inflammatory tumor-specific CD4
pubmed: 26183926
doi: 10.1158/0008-5472.CAN-14-2956
Ott, P. A. et al. An immunogenic personal neoantigen vaccine for patients with melanoma. Nature 547, 217–221 (2017).
pubmed: 28678778
pmcid: 5577644
doi: 10.1038/nature22991
Hu, Z. T. et al. Personal neoantigen vaccines induce persistent memory T cell responses and epitope spreading in patients with melanoma. Nat. Med. 27, 515–525 (2021).
pubmed: 33479501
pmcid: 8273876
doi: 10.1038/s41591-020-01206-4
Boni, A. et al. Selective BRAF
pubmed: 20551059
doi: 10.1158/0008-5472.CAN-10-0118
Frederick, D. T. et al. BRAF inhibition is associated with enhanced melanoma antigen expression and a more favorable tumor microenvironment in patients with metastatic melanoma. Clin. Cancer Res. 19, 1225–1231 (2013).
pubmed: 23307859
pmcid: 3752683
doi: 10.1158/1078-0432.CCR-12-1630
Sapkota, B., Hill, C. E. & Pollack, B. P. Vemurafenib enhances MHC induction in BRAF
pubmed: 23483066
pmcid: 3583938
doi: 10.4161/onci.22890
Acquavella, N. et al. Type I cytokines synergize with oncogene inhibition to induce tumor growth arrest. Cancer Immunol. Res. 3, 37–47 (2015).
pubmed: 25358764
doi: 10.1158/2326-6066.CIR-14-0122
Sumimoto, H., Imabayashi, F., Iwata, T. & Kawakami, Y. The BRAF–MAPK signaling pathway is essential for cancer-immune evasion in human melanoma cells. J. Exp. Med. 203, 1651–1656 (2006).
pubmed: 16801397
pmcid: 2118331
doi: 10.1084/jem.20051848
Peng, W. et al. Loss of PTEN promotes resistance to T cell-mediated immunotherapy. Cancer Discov. 6, 202–216 (2016).
pubmed: 26645196
doi: 10.1158/2159-8290.CD-15-0283
Yaguchi, T. et al. Immune suppression and resistance mediated by constitutive activation of Wnt/β-catenin signaling in human melanoma cells. J. Immunol. 189, 2110–2117 (2012).
pubmed: 22815287
doi: 10.4049/jimmunol.1102282
Spranger, S., Bao, R. Y. & Gajewski, T. F. Melanoma-intrinsic β-catenin signalling prevents anti-tumour immunity. Nature 523, 231–235 (2015).
pubmed: 25970248
doi: 10.1038/nature14404
Spranger, S., Dai, D., Horton, B. & Gajewski, T. F. Tumor-residing Batf3 dendritic cells are required for effector T cell trafficking and adoptive T cell therapy. Cancer Cell 31, 711–723.e4 (2017).
pubmed: 28486109
pmcid: 5650691
doi: 10.1016/j.ccell.2017.04.003
Chen, C. F. et al. ATR mutations promote the growth of melanoma tumors by modulating the immune microenvironment. Cell Rep. 18, 2331–2342 (2017).
pubmed: 28273450
pmcid: 5393360
doi: 10.1016/j.celrep.2017.02.040
Mehta, A. et al. Immunotherapy resistance by inflammation-induced dedifferentiation. Cancer Discov. 8, 935–943 (2018).
pubmed: 29899062
pmcid: 6076867
doi: 10.1158/2159-8290.CD-17-1178
Lee, J. H. et al. Transcriptional downregulation of MHC class I and melanoma de-differentiation in resistance to PD-1 inhibition. Nat. Commun. 11, 1897 (2020).
pubmed: 32312968
pmcid: 7171183
doi: 10.1038/s41467-020-15726-7
Paijens, S. T., Vledder, A., de Bruyn, M. & Nijman, H. W. Tumor-infiltrating lymphocytes in the immunotherapy era. Cell Mol. Immunol. 18, 842–859 (2021).
pubmed: 33139907
doi: 10.1038/s41423-020-00565-9
Tirosh, I. et al. Dissecting the multicellular ecosystem of metastatic melanoma by single-cell RNA-seq. Science 352, 189–196 (2016).
pubmed: 27124452
pmcid: 4944528
doi: 10.1126/science.aad0501
Waldman, A. D., Fritz, J. M. & Lenardo, M. J. A guide to cancer immunotherapy: from T cell basic science to clinical practice. Nat. Rev. Immunol. 20, 651–668 (2020).
pubmed: 32433532
pmcid: 7238960
doi: 10.1038/s41577-020-0306-5
Ribas, A. & Wolchok, J. D. Cancer immunotherapy using checkpoint blockade. Science 359, 1350–1355 (2018).
pubmed: 29567705
pmcid: 7391259
doi: 10.1126/science.aar4060
Yang, R. et al. Galectin-9 interacts with PD-1 and TIM-3 to regulate T cell death and is a target for cancer immunotherapy. Nat. Commun. 12, 832 (2021).
pubmed: 33547304
pmcid: 7864927
doi: 10.1038/s41467-021-21099-2
Wolf, Y., Anderson, A. C. & Kuchroo, V. K. TIM3 comes of age as an inhibitory receptor. Nat. Rev. Immunol. 20, 173–185 (2020).
pubmed: 31676858
doi: 10.1038/s41577-019-0224-6
Sade-Feldman, M. et al. Defining T cell states associated with response to checkpoint immunotherapy in melanoma. Cell 176, 404 (2019).
pubmed: 30633907
pmcid: 6647017
doi: 10.1016/j.cell.2018.12.034
da Silva, I. P. et al. Reversal of NK-cell exhaustion in advanced melanoma by Tim-3 blockade. Cancer Immunol. Res. 2, 410–422 (2014).
pubmed: 24795354
pmcid: 4046278
doi: 10.1158/2326-6066.CIR-13-0171
Fourcade, J. et al. CD8
pubmed: 22205715
doi: 10.1158/0008-5472.CAN-11-2637
Qin, S. et al. Novel immune checkpoint targets: moving beyond PD-1 and CTLA-4. Mol. Cancer 18, 155 (2019).
pubmed: 31690319
pmcid: 6833286
doi: 10.1186/s12943-019-1091-2
Quandt, D., Fiedler, E., Boettcher, D., Marsch, W. & Seliger, B. B7-H4 expression in human melanoma: its association with patients’ survival and antitumor immune response. Clin. Cancer Res. 17, 3100–3111 (2011).
pubmed: 21378130
doi: 10.1158/1078-0432.CCR-10-2268
Kuklinski, L. F. et al. VISTA expression on tumor-infiltrating inflammatory cells in primary cutaneous melanoma correlates with poor disease-specific survival. Cancer Immunol. Immunother. 67, 1113–1121 (2018).
pubmed: 29737375
doi: 10.1007/s00262-018-2169-1
Young, A. et al. Targeting adenosine in BRAF-mutant melanoma reduces tumor growth and metastasis. Cancer Res. 77, 4684–4696 (2017).
pubmed: 28652244
doi: 10.1158/0008-5472.CAN-17-0393
Lee, Y. H. et al. Inhibition of the B7-H3 immune checkpoint limits tumor growth by enhancing cytotoxic lymphocyte function. Cell Res. 27, 1034–1045 (2017).
pubmed: 28685773
pmcid: 5539354
doi: 10.1038/cr.2017.90
Lee, H. et al. Targeting NK cells to enhance melanoma response to immunotherapies. Cancers (Basel) 13, e1363 (2021).
doi: 10.3390/cancers13061363
Zhou, P. et al. In vivo discovery of immunotherapy targets in the tumour microenvironment. Nature 506, 52–57 (2014).
pubmed: 24476824
pmcid: 4052214
doi: 10.1038/nature12988
Shifrut, E. et al. Genome-wide CRISPR screens in primary human T cells reveal key regulators of immune function. Cell 175, 1958–1971.e15 (2018).
pubmed: 30449619
pmcid: 6689405
doi: 10.1016/j.cell.2018.10.024
Cabrita, R. et al. Tertiary lymphoid structures improve immunotherapy and survival in melanoma. Nature 577, 561–565 (2020).
pubmed: 31942071
doi: 10.1038/s41586-019-1914-8
Helmink, B. A. et al. B cells and tertiary lymphoid structures promote immunotherapy response. Nature 577, 549–555 (2020).
pubmed: 31942075
pmcid: 8762581
doi: 10.1038/s41586-019-1922-8
Ferrari de Andrade, L. et al. Antibody-mediated inhibition of MICA and MICB shedding promotes NK cell-driven tumor immunity. Science 359, 1537–1542 (2018).
pubmed: 29599246
pmcid: 6626532
doi: 10.1126/science.aao0505
He, W. et al. Naturally activated Vγ4 γδ T cells play a protective role in tumor immunity through expression of eomesodermin. J. Immunol. 185, 126–133 (2010).
pubmed: 20525896
doi: 10.4049/jimmunol.0903767
Exley, M. A. et al. Adoptive transfer of invariant NKT cells as immunotherapy for advanced melanoma: a phase I clinical trial. Clin. Cancer Res. 23, 3510–3519 (2017).
pubmed: 28193627
pmcid: 5511564
doi: 10.1158/1078-0432.CCR-16-0600
Petley, E. V. et al. MAIT cells regulate NK cell-mediated tumor immunity. Nat. Commun. 12, 4746 (2021).
pubmed: 34362900
pmcid: 8346465
doi: 10.1038/s41467-021-25009-4
Yan, J. et al. MAIT cells promote tumor initiation, growth, and metastases via tumor MR1. Cancer Discov. 10, 124–141 (2020).
pubmed: 31826876
doi: 10.1158/2159-8290.CD-19-0569
Miracco, C. et al. Utility of tumour-infiltrating CD25
pubmed: 17914561
Gambichler, T., Bindsteiner, M., Hoxtermann, S., Terras, S. & Kreuter, A. Circulating CD4
pubmed: 23205892
doi: 10.1111/pcmr.12055
Halaby, M. J. et al. GCN2 drives macrophage and MDSC function and immunosuppression in the tumor microenvironment. Sci. Immunol. 4, eaax8189 (2019).
pubmed: 31836669
pmcid: 7201901
doi: 10.1126/sciimmunol.aax8189
Ziani, L. et al. Melanoma-associated fibroblasts decrease tumor cell susceptibility to NK cell-mediated killing through matrix-metalloproteinases secretion. Oncotarget 8, 19780–19794 (2017).
pubmed: 28423623
pmcid: 5386721
doi: 10.18632/oncotarget.15540
Huse, M. Mechanical forces in the immune system. Nat. Rev. Immunol. 17, 679–690 (2017).
pubmed: 28757604
pmcid: 6312705
doi: 10.1038/nri.2017.74
Winkler, J., Abisoye-Ogunniyan, A., Metcalf, K. J. & Werb, Z. Concepts of extracellular matrix remodelling in tumour progression and metastasis. Nat. Commun. 11, 5120 (2020).
pubmed: 33037194
pmcid: 7547708
doi: 10.1038/s41467-020-18794-x
Kaur, A. et al. Remodeling of the collagen matrix in aging skin promotes melanoma metastasis and affects immune cell motility. Cancer Discov. 9, 64–81 (2019).
pubmed: 30279173
doi: 10.1158/2159-8290.CD-18-0193
Feng, M. et al. Phagocytosis checkpoints as new targets for cancer immunotherapy. Nat. Rev. Cancer 19, 568–586 (2019).
pubmed: 31462760
pmcid: 7002027
doi: 10.1038/s41568-019-0183-z
Chang, C. H. et al. Posttranscriptional control of T cell effector function by aerobic glycolysis. Cell 153, 1239–1251 (2013).
pubmed: 23746840
pmcid: 3804311
doi: 10.1016/j.cell.2013.05.016
Vander Heiden, M. G., Cantley, L. C. & Thompson, C. B. Understanding the Warburg effect: the metabolic requirements of cell proliferation. Science 324, 1029–1033 (2009).
doi: 10.1126/science.1160809
Swamy, M. et al. Glucose and glutamine fuel protein O-GlcNAcylation to control T cell self-renewal and malignancy. Nat. Immunol. 17, 712–720 (2016).
pubmed: 27111141
pmcid: 4900450
doi: 10.1038/ni.3439
Munn, D. H. et al. Inhibition of T cell proliferation by macrophage tryptophan catabolism. J. Exp. Med. 189, 1363–1372 (1999).
pubmed: 10224276
pmcid: 2193062
doi: 10.1084/jem.189.9.1363
Munn, D. H. et al. GCN2 kinase in T cells mediates proliferative arrest and anergy induction in response to indoleamine 2,3-dioxygenase. Immunity 22, 633–642 (2005).
pubmed: 15894280
doi: 10.1016/j.immuni.2005.03.013
Sundrud, M. S. et al. Halofuginone inhibits T
pubmed: 19498172
pmcid: 2803727
doi: 10.1126/science.1172638
Husain, Z., Huang, Y., Seth, P. & Sukhatme, V. P. Tumor-derived lactate modifies antitumor immune response: effect on myeloid-derived suppressor cells and NK cells. J. Immunol. 191, 1486–1495 (2013).
pubmed: 23817426
doi: 10.4049/jimmunol.1202702
Brand, A. et al. LDHA-associated lactic acid production blunts tumor immunosurveillance by T and NK cells. Cell Metab. 24, 657–671 (2016).
pubmed: 27641098
doi: 10.1016/j.cmet.2016.08.011
Chang, C. H. et al. Metabolic competition in the tumor microenvironment is a driver of cancer progression. Cell 162, 1229–1241 (2015).
pubmed: 26321679
pmcid: 4864363
doi: 10.1016/j.cell.2015.08.016
Stearn, E. W., Sturdivant, B. F. & Stearn, A. E. The life history of a micro-parasite isolated from carcinomatous growths. Proc. Natl Acad. Sci. USA 11, 662–669 (1925).
pubmed: 16587062
pmcid: 1086184
doi: 10.1073/pnas.11.10.662
Nejman, D. et al. The human tumor microbiome is composed of tumor type-specific intracellular bacteria. Science 368, 973–980 (2020).
pubmed: 32467386
pmcid: 7757858
doi: 10.1126/science.aay9189
Schwabe, R. F. & Jobin, C. The microbiome and cancer. Nat. Rev. Cancer 13, 800–812 (2013).
pubmed: 24132111
pmcid: 3986062
doi: 10.1038/nrc3610
Mehta, R. S. et al. Association of dietary patterns with risk of colorectal cancer subtypes classified by fusobacterium nucleatum in tumor tissue. JAMA Oncol. 3, 921–927 (2017).
pubmed: 28125762
pmcid: 5502000
doi: 10.1001/jamaoncol.2016.6374
Garrett, W. S. Cancer and the microbiota. Science 348, 80–86 (2015).
pubmed: 25838377
pmcid: 5535753
doi: 10.1126/science.aaa4972
Geller, L. T. et al. Potential role of intratumor bacteria in mediating tumor resistance to the chemotherapeutic drug gemcitabine. Science 357, 1156–1160 (2017).
pubmed: 28912244
pmcid: 5727343
doi: 10.1126/science.aah5043
Yu, T. et al. Fusobacterium nucleatum promotes chemoresistance to colorectal cancer by modulating autophagy. Cell 170, 548–563.e16 (2017).
pubmed: 28753429
pmcid: 5767127
doi: 10.1016/j.cell.2017.07.008
Chaput, N. et al. Baseline gut microbiota predicts clinical response and colitis in metastatic melanoma patients treated with ipilimumab. Ann. Oncol. 30, 2012 (2019).
pubmed: 31408090
doi: 10.1093/annonc/mdz224
Frankel, A. E. et al. Metagenomic shotgun sequencing and unbiased metabolomic profiling identify specific human gut microbiota and metabolites associated with immune checkpoint therapy efficacy in melanoma patients. Neoplasia 19, 848–855 (2017).
pubmed: 28923537
pmcid: 5602478
doi: 10.1016/j.neo.2017.08.004
Gopalakrishnan, V. et al. Gut microbiome modulates response to anti-PD-1 immunotherapy in melanoma patients. Science 359, 97–103 (2018).
pubmed: 29097493
doi: 10.1126/science.aan4236
Matson, V. et al. The commensal microbiome is associated with anti-PD-1 efficacy in metastatic melanoma patients. Science 359, 104–108 (2018).
pubmed: 29302014
pmcid: 6707353
doi: 10.1126/science.aao3290
Routy, B. et al. Gut microbiome influences efficacy of PD-1-based immunotherapy against epithelial tumors. Science 359, 91–97 (2018). Together with Gopalakrishnan et al. (2018) and Matson et al. (2018), this paper demonstrates how the diversity and composition of gut microbiome can influence the response to ICIs in melanoma and epithelial tumours. The papers also present mouse models for faecal microbiota transplant.
pubmed: 29097494
doi: 10.1126/science.aan3706
Sivan, A. et al. Commensal Bifidobacterium promotes antitumor immunity and facilitates anti-PD-L1 efficacy. Science 350, 1084–1089 (2015).
pubmed: 26541606
pmcid: 4873287
doi: 10.1126/science.aac4255
Vetizou, M. et al. Anticancer immunotherapy by CTLA-4 blockade relies on the gut microbiota. Science 350, 1079–1084 (2015).
pubmed: 26541610
pmcid: 4721659
doi: 10.1126/science.aad1329
Baruch, E. N. et al. Fecal microbiota transplant promotes response in immunotherapy-refractory melanoma patients. Science 371, 602–609 (2021).
pubmed: 33303685
doi: 10.1126/science.abb5920
Davar, D. et al. Fecal microbiota transplant overcomes resistance to anti-PD-1 therapy in melanoma patients. Science 371, 595–602 (2021). Together with Baruch et al. (2021), this paper demonstrates clinical benefits to patients with melanoma of faecal microbiota transplantation to overcome ICI resistance.
pubmed: 33542131
pmcid: 8097968
doi: 10.1126/science.abf3363
Uribe-Herranz, M. et al. Gut microbiota modulates adoptive cell therapy via CD8α dendritic cells and IL-12. JCI Insight. 3, e94952 (2018).
pmcid: 5916241
doi: 10.1172/jci.insight.94952
Tanoue, T. et al. A defined commensal consortium elicits CD8 T cells and anti-cancer immunity. Nature 565, 600–605 (2019).
pubmed: 30675064
doi: 10.1038/s41586-019-0878-z
Poore, G. D. et al. Microbiome analyses of blood and tissues suggest cancer diagnostic approach. Nature 579, 567–574 (2020). Together with Nejman et al. (2020) and Geller et al. (2017), this paper demonstrates the presence of bacteria in human tumour samples using experimental or computational methods. Geller et al. (2017) also present a bacteria-driven resistance mechanism to chemotherapy.
pubmed: 32214244
pmcid: 7500457
doi: 10.1038/s41586-020-2095-1
Zhu, G. et al. Intratumour microbiome associated with the infiltration of cytotoxic CD8
pubmed: 33962358
doi: 10.1016/j.ejca.2021.03.053
Pushalkar, S. et al. The pancreatic cancer microbiome promotes oncogenesis by induction of innate and adaptive immune suppression. Cancer Discov. 8, 403–416 (2018).
pubmed: 29567829
pmcid: 6225783
doi: 10.1158/2159-8290.CD-17-1134
Gur, C. et al. Binding of the Fap2 protein of Fusobacterium nucleatum to human inhibitory receptor TIGIT protects tumors from immune cell attack. Immunity 42, 344–355 (2015). This study presents mechanisms by which F. nucleatum evades the immune response in the melanoma TME.
pubmed: 25680274
pmcid: 4361732
doi: 10.1016/j.immuni.2015.01.010
Hamada, T. et al. Fusobacterium nucleatum in colorectal cancer relates to immune response differentially by tumor microsatellite instability status. Cancer Immunol. Res. 6, 1327–1336 (2018).
pubmed: 30228205
pmcid: 6215508
doi: 10.1158/2326-6066.CIR-18-0174
Thomas, N. E. et al. Tumor-infiltrating lymphocyte grade in primary melanomas is independently associated with melanoma-specific survival in the population-based genes, environment and melanoma study. J. Clin. Oncol. 31, 4252–4259 (2013).
pubmed: 24127443
pmcid: 3821014
doi: 10.1200/JCO.2013.51.3002
Chen, P. L. et al. Analysis of immune signatures in longitudinal tumor samples yields insight into biomarkers of response and mechanisms of resistance to immune checkpoint blockade. Cancer Discov. 6, 827–837 (2016).
pubmed: 27301722
pmcid: 5082984
doi: 10.1158/2159-8290.CD-15-1545
Tumeh, P. C. et al. PD-1 blockade induces responses by inhibiting adaptive immune resistance. Nature 515, 568–571 (2014).
pubmed: 25428505
pmcid: 4246418
doi: 10.1038/nature13954
Riaz, N. et al. Tumor and microenvironment evolution during immunotherapy with nivolumab. Cell 171, 934–949.e16 (2017).
pubmed: 29033130
pmcid: 5685550
doi: 10.1016/j.cell.2017.09.028
Rooney, M. S., Shukla, S. A., Wu, C. J., Getz, G. & Hacohen, N. Molecular and genetic properties of tumors associated with local immune cytolytic activity. Cell 160, 48–61 (2015).
pubmed: 25594174
pmcid: 4856474
doi: 10.1016/j.cell.2014.12.033
Sade-Feldman, M. et al. Defining T cell states associated with response to checkpoint immunotherapy in melanoma. Cell 175, 998–1013.e20 (2018).
pubmed: 30388456
pmcid: 6641984
doi: 10.1016/j.cell.2018.10.038
Yost, K. E. et al. Clonal replacement of tumor-specific T cells following PD-1 blockade. Nat. Med. 25, 1251–1259 (2019).
pubmed: 31359002
pmcid: 6689255
doi: 10.1038/s41591-019-0522-3
Topalian, S. L. et al. Safety, activity, and immune correlates of anti-PD-1 antibody in cancer. N. Engl. J. Med. 366, 2443–2454 (2012).
pubmed: 22658127
pmcid: 3544539
doi: 10.1056/NEJMoa1200690
Wolchok, J. D. et al. Nivolumab plus ipilimumab in advanced melanoma. N. Engl. J. Med. 369, 122–133 (2013).
pubmed: 23724867
pmcid: 5698004
doi: 10.1056/NEJMoa1302369
Robert, C. et al. Nivolumab in previously untreated melanoma without BRAF mutation. N. Engl. J. Med. 372, 320–330 (2015).
pubmed: 25399552
doi: 10.1056/NEJMoa1412082
Grasso, C. S. et al. Conserved interferon-γ signaling drives clinical response to immune checkpoint blockade therapy in melanoma. Cancer Cell 38, 500–515.e3 (2020).
pubmed: 32916126
pmcid: 7872287
doi: 10.1016/j.ccell.2020.08.005
Ayers, M. et al. IFN-γ-related mRNA profile predicts clinical response to PD-1 blockade. J. Clin. Inves. 127, 2930–2940 (2017).
doi: 10.1172/JCI91190
Snyder, A. et al. Genetic basis for clinical response to CTLA-4 blockade in melanoma. N. Engl. J. Med. 371, 2189–2199 (2014).
pubmed: 25409260
pmcid: 4315319
doi: 10.1056/NEJMoa1406498
Spranger, S. et al. Density of immunogenic antigens does not explain the presence or absence of the T-cell-inflamed tumor microenvironment in melanoma. Proc. Natl Acad. Sci. USA 113, E7759–E7768 (2016).
pubmed: 27837020
pmcid: 5137753
doi: 10.1073/pnas.1609376113
Hugo, W. et al. Genomic and transcriptomic features of response to anti-PD-1 therapy in metastatic melanoma. Cell 165, 35–44 (2016).
pubmed: 26997480
pmcid: 4808437
doi: 10.1016/j.cell.2016.02.065
Ribas, A. et al. Combined BRAF and MEK inhibition with PD-1 blockade immunotherapy in BRAF-mutant melanoma. Nat. Med. 25, 1319–1319 (2019).
pubmed: 31267021
doi: 10.1038/s41591-019-0535-y
Ascierto, P. A. et al. Dabrafenib, trametinib and pembrolizumab or placebo in BRAF-mutant melanoma. Nat. Med. 25, 941–946 (2019).
pubmed: 31171878
doi: 10.1038/s41591-019-0448-9
Sullivan, R. J. et al. Atezolizumab plus cobimetinib and vemurafenib in BRAF-mutated melanoma patients. Nat. Med. 25, 929–935 (2019).
pubmed: 31171876
doi: 10.1038/s41591-019-0474-7
Ribas, A. et al. Oncolytic virotherapy promotes intratumoral T cell infiltration and improves anti-PD-1 immunotherapy. Cell 170, 1109–1119 (2017).
pubmed: 28886381
pmcid: 8034392
doi: 10.1016/j.cell.2017.08.027
Singh, M. et al. Intratumoral CD40 activation and checkpoint blockade induces T cell-mediated eradication of melanoma in the brain. Nat. Commun. 8, 1447 (2017).
pubmed: 29129918
pmcid: 5682289
doi: 10.1038/s41467-017-01572-7
Sahin, U. et al. An RNA vaccine drives immunity in checkpoint-inhibitor-treated melanoma. Nature 585, 107–112 (2020). Together with Sahin et al. (2017), Ott et al. (2017) and Hu et al. (2021), this paper describes the use of peptide and RNA vaccines with mutated antigens or tumour-associated antigens in patients with melanoma. The success of these studies demonstrates the power of selecting the right antigens and using them for vaccines.
pubmed: 32728218
doi: 10.1038/s41586-020-2537-9
Apetoh, L. et al. Toll-like receptor 4-dependent contribution of the immune system to anticancer chemotherapy and radiotherapy. Nat. Med. 13, 1050–1059 (2007).
pubmed: 17704786
doi: 10.1038/nm1622
Twyman-Saint Victor, C. et al. Radiation and dual checkpoint blockade activate non-redundant immune mechanisms in cancer. Nature 520, 373–377 (2015).
pubmed: 25754329
doi: 10.1038/nature14292
Morgan, R. A. et al. Cancer regression in patients after transfer of genetically engineered lymphocytes. Science 314, 126–129 (2006).
pubmed: 16946036
pmcid: 2267026
doi: 10.1126/science.1129003
Stadtmauer, E. A. et al. CRISPR-engineered T cells in patients with refractory cancer. Science. 367, eaba7365 (2020).
pubmed: 32029687
doi: 10.1126/science.aba7365
Wargo, J. A. Modulating gut microbes. Science 369, 1302–1303 (2020).
pubmed: 32913089
doi: 10.1126/science.abc3965
Harlin, H. et al. Chemokine expression in melanoma metastases associated with CD8
pubmed: 19293190
doi: 10.1158/0008-5472.CAN-08-2281
Rosenberg, S. A. IL-2: the first effective immunotherapy for human cancer. J. Immunol. 192, 5451–5458 (2014).
pubmed: 24907378
doi: 10.4049/jimmunol.1490019
Zhang, S. et al. Systemic interferon-γ increases MHC class I expression and T-cell infiltration in cold tumors: results of a phase 0 clinical trial. Cancer Immunol. Res. 7, 1237–1243 (2019).
pubmed: 31171504
pmcid: 6677581
doi: 10.1158/2326-6066.CIR-18-0940
Sun, Z. et al. A next-generation tumor-targeting IL-2 preferentially promotes tumor-infiltrating CD8
pubmed: 31462678
pmcid: 6713724
doi: 10.1038/s41467-019-11782-w
Ribas, A. et al. SD-101 in combination with pembrolizumab in advanced melanoma: results of a phase Ib, multicenter study. Cancer Discov. 8, 1250–1257 (2018).
pubmed: 30154193
pmcid: 6719557
doi: 10.1158/2159-8290.CD-18-0280
Andre, P. et al. Anti-NKG2A mAb is a checkpoint inhibitor that promotes anti-tumor immunity by unleashing both T and NK cells. Cell 175, 1731–1743.e13 (2018).
pubmed: 30503213
pmcid: 6292840
doi: 10.1016/j.cell.2018.10.014
Godfrey, D. I., Le Nours, J., Andrews, D. M., Uldrich, A. P. & Rossjohn, J. Unconventional T cell targets for cancer immunotherapy. Immunity 48, 453–473 (2018).
pubmed: 29562195
doi: 10.1016/j.immuni.2018.03.009
Klebanoff, C. A., Rosenberg, S. A. & Restifo, N. P. Prospects for gene-engineered T cell immunotherapy for solid cancers. Nat. Med. 22, 26–36 (2016).
pubmed: 26735408
pmcid: 6295670
doi: 10.1038/nm.4015
Liu, E. L. et al. Use of CAR-transduced natural killer cells in CD19-positive lymphoid tumors. N. Engl. J. Med. 382, 545–553 (2020).
pubmed: 32023374
pmcid: 7101242
doi: 10.1056/NEJMoa1910607
Klichinsky, M. et al. Human chimeric antigen receptor macrophages for cancer immunotherapy. Nat. Biotechnol. 38, 947–953 (2020).
pubmed: 32361713
pmcid: 7883632
doi: 10.1038/s41587-020-0462-y
Cho, J. H. et al. Engineering advanced logic and distributed computing in human CAR immune cells. Nat. Commun. 12, 792 (2021).
pubmed: 33542232
pmcid: 7862674
doi: 10.1038/s41467-021-21078-7
Kalaora, S. et al. Use of HLA peptidomics and whole exome sequencing to identify human immunogenic neo-antigens. Oncotarget 7, 5110–5117 (2016).
pubmed: 26819371
pmcid: 4868674
doi: 10.18632/oncotarget.6960
Bassani-Sternberg, M. et al. Direct identification of clinically relevant neoepitopes presented on native human melanoma tissue by mass spectrometry. Nat. Commun. 7, 13404 (2016).
pubmed: 27869121
pmcid: 5121339
doi: 10.1038/ncomms13404
Pritchard, A. L. et al. Exploration of peptides bound to MHC class I molecules in melanoma. Pigment. Cell Melanoma Res. 28, 281–294 (2015).
pubmed: 25645385
doi: 10.1111/pcmr.12357
Robbins, P. F. et al. Mining exomic sequencing data to identify mutated antigens recognized by adoptively transferred tumor-reactive T cells. Nat. Med. 19, 747–752 (2013).
pubmed: 23644516
pmcid: 3757932
doi: 10.1038/nm.3161
Gros, A. et al. Prospective identification of neoantigen-specific lymphocytes in the peripheral blood of melanoma patients. Nat. Med. 22, 433–438 (2016).
pubmed: 26901407
pmcid: 7446107
doi: 10.1038/nm.4051
Prickett, T. D. et al. Durable complete response from metastatic melanoma after transfer of autologous T cells recognizing 10 mutated tumor antigens. Cancer Immunol. Res. 4, 669–678 (2016).
pubmed: 27312342
pmcid: 4970903
doi: 10.1158/2326-6066.CIR-15-0215
Lennerz, V. et al. The response of autologous T cells to a human melanoma is dominated by mutated neoantigens. Proc. Natl Acad. Sci. USA 102, 16013–16018 (2005).
pubmed: 16247014
pmcid: 1266037
doi: 10.1073/pnas.0500090102
Linnemann, C. et al. High-throughput epitope discovery reveals frequent recognition of neo-antigens by CD4
pubmed: 25531942
doi: 10.1038/nm.3773
Andersen, R. S. et al. Dissection of T-cell antigen specificity in human melanoma. Cancer Res. 72, 1642–1650 (2012).
pubmed: 22311675
doi: 10.1158/0008-5472.CAN-11-2614
Kvistborg, P. et al. TIL therapy broadens the tumor-reactive CD8
pubmed: 22754759
pmcid: 3382882
doi: 10.4161/onci.18851
Cohen, C. J. et al. Isolation of neoantigen-specific T cells from tumor and peripheral lymphocytes. J. Clin. Invest. 125, 3981–3991 (2015).
pubmed: 26389673
pmcid: 4607110
doi: 10.1172/JCI82416
The Human Microbiome Project Consortium. A framework for human microbiome research. Nature 486, 215–221 (2012).
doi: 10.1038/nature11209
DeSantis, T. Z. et al. Greengenes, a chimera-checked 16S rRNA gene database and workbench compatible with ARB. Appl. Env. Microbiol. 72, 5069–5072 (2006).
doi: 10.1128/AEM.03006-05
Quast, C. et al. The SILVA ribosomal RNA gene database project: improved data processing and web-based tools. Nucleic Acids Res. 41, D590–D596 (2013).
pubmed: 23193283
doi: 10.1093/nar/gks1219
Cole, J. R. et al. Ribosomal Database Project: data and tools for high throughput rRNA analysis. Nucleic Acids Res. 42, D633–D642 (2014).
pubmed: 24288368
doi: 10.1093/nar/gkt1244
Zhang, J. et al. Evaluation of different 16S rRNA gene V regions for exploring bacterial diversity in a eutrophic freshwater lake. Sci. Total. Env. 618, 1254–1267 (2018).
doi: 10.1016/j.scitotenv.2017.09.228
Bashiardes, S., Zilberman-Schapira, G. & Elinav, E. Use of metatranscriptomics in microbiome research. Bioinform Biol. Insights 10, 19–25 (2016).
pubmed: 27127406
pmcid: 4839964
doi: 10.4137/BBI.S34610
Seng, P. et al. Ongoing revolution in bacteriology: routine identification of bacteria by matrix-assisted laser desorption ionization time-of-flight mass spectrometry. Clin. Infect. Dis. 49, 543–551 (2009).
pubmed: 19583519
doi: 10.1086/600885
Clark, A. E., Kaleta, E. J., Arora, A. & Wolk, D. M. Matrix-assisted laser desorption ionization-time of flight mass spectrometry: a fundamental shift in the routine practice of clinical microbiology. Clin. Microbiol. Rev. 26, 547–603 (2013).
pubmed: 23824373
pmcid: 3719498
doi: 10.1128/CMR.00072-12